Iron-Chelating Therapy for Transfusional Iron Overload
نویسندگان
چکیده
منابع مشابه
Management of transfusional iron overload – differential properties and efficacy of iron chelating agents
Regular red cell transfusion therapy ameliorates disease-related morbidity and can be lifesaving in patients with various hematological disorders. Transfusion therapy, however, causes progressive iron loading, which, if untreated, results in endocrinopathies, cardiac arrhythmias and congestive heart failure, hepatic fibrosis, and premature death. Iron chelation therapy is used to prevent iron l...
متن کاملRole of deferiprone in chelation therapy for transfusional iron overload.
Before 1987, iron chelation therapy for patients with thalassemia major and other refractory anemias requiring regular transfusions depended almost entirely on one drug, deferoxamine. The drug has dramatically increased survival in patients with thalassemia major in countries where it is readily available.1,2 Although many other compounds had been tried as iron-chelating agents in experiments w...
متن کاملMR characterization of hepatic storage iron in transfusional iron overload.
PURPOSE To quantify the two principal forms of hepatic storage iron, diffuse, soluble iron (primarily ferritin), and aggregated, insoluble iron (primarily hemosiderin) using a new MRI method in patients with transfusional iron overload. MATERIALS AND METHODS Six healthy volunteers and 20 patients with transfusion-dependent thalassemia syndromes and iron overload were examined. Ferritin- and h...
متن کاملHow I treat transfusional iron overload.
Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measu...
متن کاملOverview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2011
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmct1004810